Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

95.75 -0.65 (-0.67%)

Streaming Delayed Price Updated: 10:58 AM EDT, Apr 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

March 10, 2023

Via Benzinga

Analyst Expectations for Mirum Pharmaceuticals's Future ↗

March 09, 2023

Via Benzinga

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

March 08, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023

March 01, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals's Return On Capital Employed Insights ↗

December 14, 2022

Via Benzinga

Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease ↗

December 13, 2022

Via Benzinga

Where Mirum Pharmaceuticals Stands With Analysts ↗

November 10, 2022

Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings:

Via Benzinga

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

Earnings Preview: Mirum Pharmaceuticals ↗

March 07, 2023

Via Benzinga

Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

February 14, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

February 09, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

January 10, 2023

Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...

Via Benzinga

Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates

January 09, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

January 03, 2023

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors

December 19, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older

December 13, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Provides Development Program Updates

November 29, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 18, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Robinhood, MicroStrategy And Other Big Losers From Wednesday ↗

November 10, 2022

U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday ↗

November 10, 2022

Gainers

Via Benzinga

Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session ↗

November 09, 2022

Gainers

Via Benzinga

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

November 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD

November 07, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

November 01, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases

October 31, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday ↗

October 26, 2022

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

All News about Mirum Pharmaceuticals, Inc. - common stock